Menu
Recruiting NCT07483554

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Phase II Interventional CLDN18.2 Positive Gastric/Gastroesophageal Junction Adenocarcinoma Pancreatic Ductal Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: IBI343,Gemcitabine, Albumin-bound Paclitaxel.
Who it may be relevant to
Registry conditions: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.

Overview

A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.

Interventions

  • Drug IBI343,Gemcitabine, Albumin-bound Paclitaxel
    IBI343,Gemcitabine, Albumin-bound Paclitaxel intravenous infusion

Primary outcome measures

  • Objective Response Rate (ORR) evaluated according to RECIST v1.1 [Time frame: Up to 24 months]
  • Incidence of Adverse Events (AE) [Time frame: Up to 24 months]
  • Incidence of treatment-emergent adverse Events (TEAE) [Time frame: Up to 24 months]
  • Incidence of adverse events of Special Interest (AESI) [Time frame: Up to 24 months]
  • Incidence of serious adverse events (SAE) [Time frame: Up to 24 months]
  • Number of participants with abnormal laboratory tests results [Time frame: Up to 24 months]
  • Number of subjects with clinically significant changes in physical examination results [Time frame: Up to 24 months]
  • Number of subjects with clinically significant changes in vital signs [Time frame: Up to 24 months]
Secondary outcome measures (12)
  • Duration of Response (DoR) evaluated according to RECIST v1.1 [Time frame: Up to 24 months]
  • Disease Control Rate (DCR) evaluated according to RECIST v1.1 [Time frame: Up to 24 months]
  • Time to Response (TTR) evaluated according to RECIST v1.1 [Time frame: Up to 24 months]
  • Progression-Free Survival (PFS) evaluated according to RECIST v1.1 [Time frame: Up to 24 months]
  • Overall Survival (OS) [Time frame: Time to death]
  • Area under the concentration-time curve for subjects receiving IBI343 treatment [Time frame: Up to 24 months]
  • Peak concentration for subjects receiving IBI343 treatment [Time frame: Up to 24 months]
  • Time to peak concentration for subjects receiving IBI343 treatment [Time frame: Up to 24 months]
  • Trough concentration for subjects receiving IBI343 treatment [Time frame: Up to 24 months]
  • Clearance for subjects receiving IBI343 treatment. [Time frame: Up to 24 months]
  • Apparent volume of distribution for subjects receiving IBI343 treatment. [Time frame: Up to 24 months]
  • Half-life for subjects receiving IBI343 treatment. [Time frame: Up to 24 months]

Eligibility criteria

Inclusion criteria

  • Signed written informed consent, willing and able to comply with the protocol-specified visits and related procedures.
  • At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  • Age ≥ 18 years, no gender restrictions.
  • An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Expected survival ≥ 12 weeks.
  • Adequate bone marrow and organ function.
  • Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must use effective contraception throughout the treatment period and for 6 months after the end of treatment.
  • Confirmed CLDN18.2 positive by central laboratory pathological tissue testing.

Exclusion criteria

  • Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.
  • Received treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug.
  • Received the last anti-tumor treatment within 4 weeks or 5 half-lives of the anti-tumor therapy (whichever is shorter) before the first dose of the investigational drug.
  • Received therapeutic or palliative radiotherapy within 2 weeks prior to the first dose of the investigational drug.
  • Underwent biliary stent placement within 7 days prior to the first dose of the investigational drug.
  • Planning to receive other anti-tumor treatments during the period of treatment with the investigational drug.
  • Received any live vaccine within 4 weeks prior to the first dose of the investigational drug or planning to receive any live vaccine during the study.
  • Underwent major surgery within 4 weeks prior to the first dose of the investigational drug, or has unhealed wounds, ulcers, or fractures; or plans to undergo major surgery during the study.
  • Has not recovered from toxicity caused by previous treatment to grade 0 or 1 according to NCI CTCAE v5.0 prior to the first dose of the investigational drug.
  • History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that was not cured by surgical treatment.
  • Presence of pyloric obstruction and/or persistent recurrent vomiting.
  • Post-procedure of stent implantation in the digestive tract or trachea.
  • Symptomatic central nervous system metastasis.
  • Bone metastasis with risk of paraplegia.
  • Interstitial lung disease requiring steroid treatment, or history of interstitial lung disease, non-infectious pneumonia, severe impairment of pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having these diseases during the screening period.
  • Presence of uncontrolled disease.
  • History of other primary malignant tumors.
  • Known history of immunodeficiency.
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Previous treatment with topoisomerase inhibitor-based antibody-drug conjugates.
  • For subjects receiving drug treatment, a history of allergy to the corresponding drug or formulation.
  • For subjects receiving drug treatment, contraindications for the corresponding drug.
  • For subjects receiving drug treatment, a history of permanent discontinuation of the corresponding drug due to related adverse reactions.
  • Pregnant or lactating female subjects.
  • Other conditions deemed unsuitable for participation in this study by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou

Identifiers

NCT: NCT07483554 · CIBI343A201

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗